Indeed, the concomitant presence of obesity-associated factors weakened the AdipoRon-mediated anticancer effects in PDAC, since both body weight and orthotopic tumor growth were slightly affected in diet-induced obese prediabetic mice by that kind of Acrp30 agonist [58]. Here, ADIPOQ is linked to neoplasm.